keyword
MENU ▼
Read by QxMD icon Read
search

Esophagogastric junction adenocarcinoma

keyword
https://www.readbyqxmd.com/read/28207537/lymph-node-dissection-for-siewert-ii-esophagogastric-junction-adenocarcinoma-a-retrospective-study-of-3-surgical-procedures
#1
Xiao-Feng Duan, Jie Yue, Peng Tang, Xiao-Bin Shang, Hong-Jing Jiang, Zhen-Tao Yu
The present study was aimed to investigate the application of right thansthoracic Ivor-Lewis (IL), left transthoracic (LTT), and left thoracoabdominal (LTA) approach in Siewert type II adenocarcinoma of esophagogastric junction (AEG).The data of 196 patients with Siewert type II AEG received surgical resection in our cancer center between January 2014 and April 2016 was retrospectively analyzed. Finally, 136 patients met the inclusion criteria were enrolled in the study and divided into the IL (47 cases), LTT (51 cases), and LTA group (38 cases)...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28174399/-treatment-strategy-for-esophagogastric-junction-carcinoma-highly-controversial-topic-in-the-upper-gastrointestinal-malignancy
#2
Hiroharu Yamashita, Yasuyuki Seto
Among the 3 subtypes of adenocarcinoma of the esophagogastric junction (AEG), Siewert type I is basically consistent with esophageal adenocarcinoma arising from the Barrett epithelium( Barrett's adenocarcinoma), and type III is gastric carcinoma with esophageal invasion over the esophagogastric junction(EGJ). It is generally endorsed that type I is treated as an esophageal carcinoma, and type III as a gastric carcinoma. Siewert type II carcinoma, located just at the borderline between the esophagus and the stomach, has been a highly controversial topic regarding surgical approach, extent of esophagogastric resection and lymphadenectomy, type of reconstruction, and even the staging system...
January 2017: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/28173664/-pathology-consensus-of-gastroesophageal-reflux-disease-barrett-s-esophagus-and-adenocarcinoma-of-esophagogastric-junction
#3
(no author information available yet)
No abstract text is available yet for this article.
February 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/28168205/role-of-nampt-and-visceral-adiposity-in-esophagogastric-junction-adenocarcinoma
#4
Haijun Li, E Bai, Yong Zhang, Zhuoqi Jia, Shicai He, Junke Fu
Nampt including eNampt and iNampt may contribute to mediating obesity-associated cancers. This study investigated the role of Nampt in esophagogastric junction adenocarcinoma (EGA), a cancer strongly correlated with obesity. Visceral adiposity was defined by waist circumference or VFA. eNampt in sera were measured by enzyme-linked immunosorbent assay. iNampt expression in EGA was determined by PCR, western blot, and immunohistochemistry. Sera eNampt were significantly elevated in these overweight and obese patients, especially for viscerally obese patients, and positively correlated with BMI, waist circumference, VFA, and also primary tumor, regional lymph nodes, and TNM stage (P < 0...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28133262/-a-case-of-recurrent-esophagogastric-junction-cancer-responding-to-trastuzumab
#5
Yuta Kobayashi, Motohiro Hirao, Kazuyoshi Yamamoto, Kazuhiro Nishikawa, Sakae Maeda, Mamoru Uemura, Masakazu Miyake, Naoki Hama, Atsushi Miyamoto, Michihiko Miyazaki, Masataka Ikeda, Shoji Nakamori, Mitsugu Sekimoto, Kiyoshi Mori, Masayuki Mano
We report a case of recurrent esophagogastric junction cancer successfully treated with chemotherapy including trastuzumab. A 66-year-old man reporting black stool was examined, and through upper gastrointestinal endoscopy was found to have a tumor at the esophagogastric junction. Video-assisted thoracoscopic surgery of the esophagus with 3-field lymph node dissection was performed. The final diagnosis was adenocarcinoma(tub1-pap-muc), pT3N3M0, pStage III C. The tumor was at the squamo-columnar junction and classified as Siewert type II ...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133205/-a-case-of-successful-multidisciplinary-therapy-for-advanced-esophagogastric-junction-cancer-with-multiple-lymph-node-metastase
#6
Kohei Murakami, Shigeyuki Tamura, Atsushi Takeno, Tomo Ishida, Ryuichi Kuwahara, Yasuki Akiyama, Takuya Sakamoto, Junichi Inatome, Atsushi Naito, Yoshiteru Katsura, Yoshiaki Ohmura, Yoshinori Kagawa, Chiyomi Egawa, Yutaka Takeda, Takeshi Kato
A 64-year-old man reporting dysphagia was examined. Upper gastrointestinal endoscopy showed a type 3 cancer at the esophagogastric junction. Enhanced CT scan showed several swollen mediastinal and abdominal lymph nodes. We diagnosed the patient with advanced adenocarcinoma of the esophagogastric junction with multiple lymph node metastases(Siewert type II , cT3N2M1[LYM], Stage IV ). After 5 courses of chemotherapy(S-1 plus cisplatin), a significant reduction was observed in the size of the tumor and lymph nodes...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28100248/mediastinal-lymph-node-dissection-and-distal-esophagectomy-is-not-essential-in-early-esophagogastric-junction-adenocarcinoma
#7
In-Seob Lee, Ji-Yong Ahn, Jeong-Hwan Yook, Byung-Sik Kim
BACKGROUND: Optimal extent of surgery remains controversial in types 2 and 3 adenocarcinoma of esophagogastric junction (AEG). We aimed to determine whether the extended procedure including mediastinal lymphadenectomy is essential in all patients with AEG by comparing prognosis and recurrence of proximal gastric adenocarcinoma based on total gastrectomy with intra-abdominal lymphadenectomy. METHODS: The clinicopathologic characteristics of 672 patients (type 2: 90, type 3: 211, upper third of the stomach: 371 cases) who underwent curative total gastrectomy with lymphadenectomy between 2003 and 2009 were reviewed...
January 18, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28078108/egfr-family-and-cmet-expression-profiles-and-prognostic-significance-in-esophagogastric-adenocarcinoma
#8
Ellie Chan, Ahmad Alkhasawneh, Lizette Vila Duckworth, Tabish Aijaz, Tania Zuluaga Toro, Xiaomin Lu, Steven J Hughes, Amy Collinsworth, Thomas J George
BACKGROUND: Targeted therapy with anti-human epidermal growth factor receptor-2 (HER2) monoclonal antibody in patients with HER2 overexpressed esophagogastric adenocarcinoma (EGA) improves survival; however, the effect is transient due to the development of resistance. Some studies suggest that cMet overexpression provides cross talk for epidermal growth factor receptor (EGFR) and HER2 inhibition. We sought to characterize the expression profile of the EGFR family and cMet receptors in untreated, resected EGA...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28054539/erratum-the-postoperative-complication-for-adenocarcinoma-of-esophagogastric-junction
#9
(no author information available yet)
[This corrects the article DOI: 10.4103/0973-1482.163867.].
July 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28039533/western-strategy-for-egj-carcinoma
#10
Simone Giacopuzzi, Maria Bencivenga, Jacopo Weindelmayer, Giuseppe Verlato, Giovanni de Manzoni
In this paper, the epidemiological and clinicobiological behavior of esophagogastric junction (EGJ) adenocarcinoma in the West is compared and contrasted to that in the East, and an overview is provided of current therapeutic strategies employed for this type of tumor in Western countries. It is well known that multimodal treatment is the therapeutic standard in locally advanced EGJ adenocarcinoma, but whether neoadjuvant/perioperative chemotherapy (CT) or neoadjuvant chemoradiotherapy (CRT) is the optimal approach is still debated...
December 30, 2016: Gastric Cancer
https://www.readbyqxmd.com/read/27995482/comparison-of-long-term-outcomes-of-endoscopic-submucosal-dissection-and-surgery-for-esophagogastric-junction-adenocarcinoma
#11
Eun Jeong Gong, Do Hoon Kim, Ji Yong Ahn, Kee Wook Jung, Jeong Hoon Lee, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung, Hee Sung Kim, In-Seob Lee, Beom Su Kim, Moon-Won Yoo, Sung Tae Oh, Jeong Hwan Yook, Byung Sik Kim
BACKGROUND: Endoscopic submucosal dissection (ESD) has become accepted as the standard treatment for early gastric cancer. However, comparative outcomes of ESD and surgery have not been evaluated for adenocarcinoma in the esophagogastric junction (EGJ). We investigated the long-term outcomes of ESD compared with those of surgery for adenocarcinoma in the EGJ. METHODS: Patients who underwent ESD or surgery for Siewert type II adenocarcinoma between 2005 and 2010 and who met the absolute and expanded criteria for endoscopic resection were eligible...
December 19, 2016: Gastric Cancer
https://www.readbyqxmd.com/read/27981384/laparoscopic-assisted-versus-open-total-gastrectomy-for-siewert-type-ii-and-iii-esophagogastric-junction-carcinoma-a-propensity-score-matched-case-control-study
#12
Chang-Ming Huang, Chen-Bin Lv, Jian-Xian Lin, Qi-Yue Chen, Chao-Hui Zheng, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Long-Long Cao, Mi Lin, Ru-Hong Tu
BACKGROUND: Few studies have evaluated the outcomes of laparoscopic-assisted total gastrectomy (LATG) for Siewert type II and III adenocarcinoma of the esophagogastric junction (AEG). Thus, aim of this study was to investigate the surgical outcomes of LATG for Siewert type II and III AEG. METHODS: Clinical data for 700 Siewert type II and III AEG patients were analyzed retrospectively. The short- and long-term outcomes were compared between the matched groups using a propensity score matching method...
December 15, 2016: Surgical Endoscopy
https://www.readbyqxmd.com/read/27938582/-short-term-outcomes-of-minimally-invasive-sweet-esophagectomy-for-siewert-type-%C3%A2-esophagogastric-junction-adenocarcinoma
#13
C Q Liu, M R Xie, M F Guo, X H Sun, H R Wu, X X Sun, M Q Xu
Objective: To describe the technique for minimally invasive Sweet esophagectomy and to evaluate the feasibility, safety and the short-term clinical outcomes of this approach in the treatment of Siewert type Ⅱ esophagogastric junction adenocarcinoma. Methods: The clinical data of 122 patients with Siewert type Ⅱ esophagogastric junction adenocarcinoma who received Sweet esophagectomy between October 2013 and June 2015 in Department of Thoracic Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University was analyzed retrospectively...
1, 2016: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/27905172/recommendations-for-pathologic-staging-ptnm-of-cancer-of-the-esophagus-and-esophagogastric-junction-for-the-8th-edition-ajcc-uicc-staging-manuals
#14
T W Rice, H Ishwaran, W L Hofstetter, D P Kelsen, C Apperson-Hansen, E H Blackstone
We report analytic and consensus processes that produced recommendations for pathologic stage groups (pTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration provided data for 22,654 patients with epithelial esophageal cancers; 13,300 without preoperative therapy had pathologic assessment after esophagectomy or endoscopic treatment. Risk-adjusted survival for each patient was developed using random survival forest analysis to identify data-driven pathologic stage groups wherein survival decreased monotonically with increasing group, was distinctive between groups, and homogeneous within groups...
November 2016: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/27905171/recommendations-for-clinical-staging-ctnm-of-cancer-of-the-esophagus-and-esophagogastric-junction-for-the-8th-edition-ajcc-uicc-staging-manuals
#15
Thomas W Rice, Hemant Ishwaran, Eugene H Blackstone, Wayne L Hofstetter, David P Kelsen, Carolyn Apperson-Hansen
We report analytic and consensus processes that produced recommendations for clinical stage groups (cTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration (WECC) provided data on 22,123 clinically staged patients with epithelial esophageal cancers. Risk-adjusted survival for each patient was developed using random survival forest analysis from which (1) data-driven clinical stage groups were identified wherein survival decreased monotonically and was distinctive between and homogeneous within groups and (2) data-driven anatomic clinical stage groups based only on cTNM...
November 2016: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/27905170/recommendations-for-neoadjuvant-pathologic-staging-yptnm-of-cancer-of-the-esophagus-and-esophagogastric-junction-for-the-8th-edition-ajcc-uicc-staging-manuals
#16
Thomas W Rice, Hemant Ishwaran, David P Kelsen, Wayne L Hofstetter, Carolyn Apperson-Hansen, Eugene H Blackstone
We report analytic and consensus processes that produced recommendations for neoadjuvant pathologic stage groups (ypTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration provided data for 22,654 patients with epithelial esophageal cancers; 7,773 had pathologic assessment after neoadjuvant therapy. Risk-adjusted survival for each patient was developed. Random forest analysis identified data-driven neoadjuvant pathologic stage groups wherein survival decreased monotonically with increasing group, was distinctive between groups, and homogeneous within groups...
November 2016: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/27904785/overexpression-of-ywhaz-as-an-independent-prognostic-factor-in-adenocarcinoma-of-the-esophago-gastric-junction
#17
Nobuyuki Watanabe, Shuhei Komatsu, Daisuke Ichikawa, Mahito Miyamae, Takuma Ohashi, Wataru Okajima, Toshiyuki Kosuga, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Kazuma Okamoto, Hitoshi Tsuda, Eigo Otsuji
Several studies have demonstrated that YWHAZ (14-3-3ζ), included in the 14-3-3 family of proteins, is implicated in the initiation and progression of cancers. To detect a novel treatment target for adenocarcinoma of the esophagogastric junction (AEG), we tested whether YWHAZ acted as a cancer-promoting gene through its overexpression in AEG. We analyzed YWHAZ protein expression in 92 consecutive primary AEG tumors, which had been curatively resected in our institution between 2000 and 2010. Overexpression of the YWHAZ protein was frequently detected in primary AEG tumor samples (46% (42/92))...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27889780/targeted-treatment-of-esophagogastric-cancer
#18
Hans-Georg Kopp, Ralf-Dieter Hofheinz
Adenocarcinoma of the esophagogastric junction (EGJ) and stomach remains one of the most common causes of cancer-related death worldwide. Although there is increasing data on the mutational landscape of esophagogastric cancer, phase III trials often yield negative results, and there is a paucity of approved targeted agents. For the time being, the subset of patients carrying HER2-positive metastatic tumors can receive trastuzumab in addition to chemotherapy. Furthermore, ramucirumab has been found to be active both as a single agent and in combination with paclitaxel...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27854106/expression-of-cyclooxygenase-2-has-no-impact-on-survival-in-adenocarcinoma-of-the-esophagogastric-junction-but-is-associated-with-favourable-clinicopathologic-features
#19
Juliana Knief, Katharina Reddemann, Ekaterina Petrova, Tobias Herhahn, Ulrich Wellner, Christoph Thorns
: Background COX-2 expression induces carcinogenesis and is thought to be an adverse prognostic factor in gastric carcinomas while the prognostic value of DNA mismatch repair (MMR) is still controversial. Concerning adenocarcinomas of the esophagogastric junction, no comprehensive data regarding either factors are available as of yet. Objective We assessed expression of COX-2, MLH1 and MSH2 in adenocarcinoma of the esophagogastric junction in relation to patients' survival and various clinicopathologic features...
November 17, 2016: Histology and Histopathology
https://www.readbyqxmd.com/read/27810391/cancer-of-the-esophagus-and-esophagogastric-junction-an-eighth-edition-staging-primer
#20
Thomas W Rice, Hemant Ishwaran, Mark K Ferguson, Eugene H Blackstone, Peter Goldstraw
This primer for eighth edition staging of esophageal and esophagogastric epithelial cancers presents separate classifications for the clinical (cTNM), pathologic (pTNM), and postneoadjuvant pathologic (ypTNM) stage groups, which are no longer shared. For pTNM, pT1 has been subcategorized as pT1a and pT1b for the subgrouping pStage I adenocarcinoma and squamous cell carcinoma. A new, simplified esophagus-specific regional lymph node map has been introduced. Undifferentiated histologic grade (G4) has been eliminated; additional analysis is required to expose histopathologic cell type...
January 2017: Journal of Thoracic Oncology
keyword
keyword
114728
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"